Amgen Sensipar Approved; Target U.S. Market At Least 300,000 Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Cinacalcet is indicated for the treatment of hyperparathyroidism associated with kidney disease and hypercalcemia in parathyroid cancer patients.
You may also be interested in...
Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market
Amgen's oral calcimimetic Sensipar faces generic competition in 2018, but the new intravenuous Parsabiv has advantages that could make it the more popular alternative.
Amgen Satisfied With Mixed Cinacalcet Cost-Effectiveness Recommendation
NICE determination limits recommended use to severe refractory SHPT patients.
Amgen Satisfied With Mixed Cinacalcet Cost-Effectiveness Recommendation
NICE determination limits recommended use to severe refractory SHPT patients.